approval · primary record
DOXORUBICIN HYDROCHLORIDE
FDA · NDA · 2026-03-10
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-03-10 |
| Approval events | 1 |
| Brand | DOXIL (LIPOSOMAL) |
| Sponsor | BAXTER HLTHCARE CORP |
| Route | INJECTION |
Approval history
1 action on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-03-10 | FDA | NDA | DOXIL (LIPOSOMAL) | BAXTER HLTHCARE CORP | INJECTION |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:32:14.385Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:doxorubicin-hydrochloride
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Doxorubicin Hydrochloride · compound